← Back to Home

A Drug That Gels in the Gut: Cosmo’s Phase 2 Ulcerative Colitis Trial Meets Remission Endpoint

A locally administered rifamycin formulation showed an efficacy signal in a six-week trial, but the primary analysis included only 60 of the 76 participants. Whether the difference can be reproduced in more comprehensive, longer-term studies will be key to further development.

By SURL BioNews

For patients with ulcerative colitis whose inflammation is concentrated in the distal colon and rectum, delivering medication to the affected sites and maintaining local activity is one approach to treatment development. Cosmo announced on October 19 that its locally acting 1% rifamycin gel met the primary efficacy endpoint in a Phase 2 trial: at six weeks, clinical remission rates in the primary analysis population were 46.2% in the treatment group and 14.3% in the placebo group. This provides preliminary clinical support for the new formulation but is not sufficient to establish long-term efficacy.

The formulation is administered as a liquid enema and turns into an adherent gel after entering the bowel, with the aim of delivering the drug to the distal colon and rectum. The company proposed that rifamycin’s antibacterial activity may influence host immune responses through the gut microbiota; however, the remission data released so far cannot directly confirm this mechanism of action.

The randomized, double-blind, placebo-controlled trial enrolled 76 patients with mild to moderately active distal ulcerative colitis or ulcerative proctitis, assigned in a 2:1 ratio to receive the drug or placebo once daily for six weeks. Clinical remission required a total Mayo score of no more than 2, a rectal bleeding subscore of 0, and stool frequency and endoscopic subscores of 0 or 1 each. The assessment therefore incorporated endoscopic findings in the bowel as well as patients’ reported symptoms.

The number of patients analyzed is particularly important when interpreting the results. According to the announcement, the primary analysis included 60 patients who completed the study and had no major eligibility violations affecting the results: 39 in the treatment group and 21 in the placebo group. The difference in remission rates between the groups was 31.9 percentage points and was statistically significant (p = 0.0190). However, this was not an analysis of all 76 participants; the reasons for excluding the remaining patients and how their data were handled still require clarification in the full report.

Regarding safety, the company reported 8 drug-related adverse events and 3 serious adverse events during the study, with all of the latter judged unrelated to treatment. The number of events is not the same as the number of people who experienced them. Without detailed classifications and a breakdown by group, it is also difficult to compare risks between the two groups. A small, six-week trial cannot adequately address safety questions concerning repeated courses or long-term use.

The publicly available information remains preliminary results released by the company. Coverage of the same event on MarketScreener and Stock Titan also derives from that announcement and cannot be considered independent verification. Secondary and exploratory endpoints are still being analyzed, and full results are expected to be presented at a future medical conference. The trial also did not directly compare the formulation with existing treatments, so its relative efficacy cannot yet be determined from these findings.

Cosmo plans to discuss the results with the U.S. Food and Drug Administration and the European Medicines Agency to plan the next stage of development. The questions ahead extend beyond whether remission can be induced within six weeks to how long the effect lasts after treatment stops and whether a larger trial can reproduce the difference observed here. These data will determine whether this locally gelling drug delivery design can progress toward becoming a treatment option available to patients.

References

  1. Cosmo / Newsfile
  2. Cosmo / Newsfile via MarketScreener
  3. Cosmo / Newsfile via Stock Titan